McVicar announces new order to Changlong

    Trading Symbol: MCV

    TORONTO, Nov. 29 /CNW/ - McVicar Resources Inc. ("McVicar") is pleased to
announce that one of its China-based subsidiaries, Hangzhou Changlong Chemical
Co. Ltd. ("Changlong") has reached an agreement with a publicly listed Chinese
pharmaceutical company for the purchase of its intermediate chemical,
N-Ethylpiperazine, for use in Asthma drugs. The size of the order is 200
tonnes, valued at approximately 12 million RMB (~CDN $1.6 million) and is to
be delivered in 2008. N-Ethylpiperazine is one of the key products for
Changlong's Piperazine series and has experienced rapid order growth since the
end of 2006.
    Changlong is a specialized developer and manufacturer of chemical
intermediates for the pharmaceutical market. The main products are piperazine
derivatives and pyridine derivatives. The company was founded in 1996 with
approximately 100 employees. Changlong is among the top in expertise in China
in reaction technology, particularly high pressure hydrogenation and
ammonification. McVicar's chemical subsidiary, McVicar (Hongkong) Advanced
Materials Co. Ltd. ("MAM") acquired 100% interest in Hongzhou Changlong
Chemical Co. Ltd. ("Changlong"), China, in October, 2007. Changlong's product
lines complement McVicar's other subsidiary Hongbo's existing portfolio in the
pharmaceutical markets.
    "This is another encouraging development from our Chinese subsidiaries",
commented Dr. Gang Chai, President & CEO of McVicar, "With the increasing
market demand for quality and stable medicines in China, Changlong stands a
much better opportunity than its peers to grow its sales and market share
based on the company's advanced technology".

    This press release contains forward-looking statements which reflect the
Corporation's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual results
could differ materially from those projected herein. Although we believe that
our expectations are based on reasonable assumptions, we can give no assurance
that our expectations will materialize.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.

For further information:

For further information: Dr. Gang Chai at: 55 University Avenue, Suite
605, Toronto, ON, M5J 2H7, Tel: (416) 366-7420, Fax (416) 366-7421,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890